ArticleOncotarget2014
Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- From plant hormones to human health: progress and challenges in strigolactone biosynthetic structural diversity and antitumor effects.Frontiers in plant science · 2026Review
- Allies or Enemies? The Power of Plant Hormones in Animals: Insights into Their Regulatory Roles.Molecules (Basel, Switzerland) · 2025Review
- A multifaceted assessment of strigolactone GR24 and its derivatives: from anticancer and antidiabetic activities to antioxidant capacity and beyond.Frontiers in molecular biosciences · 2023Review
- A novel chemo-phenotypic method identifies mixtures of salpn, vitamin D3, and pesticides involved in the development of colorectal and pancreatic cancer.Ecotoxicology and environmental safety · 2022Article
- Strigolactone Analogs: Two New Potential Bioactiphores for Glioblastoma.ACS chemical neuroscience · 2022Article
- Strigolactones, from Plants to Human Health: Achievements and Challenges.Molecules (Basel, Switzerland) · 2021Review
- Article
- Conditional reprogramming: next generation cell culture.Acta pharmaceutica Sinica. B · 2020Review
- Culture and application of conditionally reprogrammed primary tumor cells.Gastroenterology report · 2020Review
- Conditional reprogramming: Modeling urological cancer and translation to clinics.Clinical and translational medicine · 2020Review
- Strigolactone Analogs Are Promising Antiviral Agents for the Treatment of Human Cytomegalovirus Infection.Microorganisms · 2020Article
- Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks.Cells · 2019Review
- The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.Molecular cancer research : MCR · 2019Article
- Metabolic and lipidomic investigation of the antiproliferative effects of coronatine against human melanoma cells.Scientific reports · 2019Article
- Gene Ontology and Expression Studies of Strigolactone Analogues on a Hepatocellular Carcinoma Cell Line.Analytical cellular pathology (Amsterdam) · 2019Article
- Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells.Oncotarget · 2018Article
- Strigolactones-a novel class of phytohormones as anti-cancer agents.Journal of pesticide science · 2018Article
- Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells.Oncotarget · 2018Article
- Strigolactone GR24 upregulates target genes of the cytoprotective transcription factor Nrf2 in skeletal muscle.F1000Research · 2018Article
- Strigolactones: a plant phytohormone as novel anti-inflammatory agents.MedChemComm · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Strigolactones are a novel class of plant hormones produced in roots and regulate shoot and root development. We have previously shown that synthetic strigolactone analogues potently inhibit growth of breast cancer cells and breast cancer stem cells. Here we show that strigolactone analogues inhibit the growth and survival of an array of cancer-derived cell lines representing solid and non-solid cancer cells including: prostate, colon, lung, melanoma, osteosarcoma and leukemic cell lines, while normal cells were minimally affected. Treatment of cancer cells with strigolactone analogues was hallmarked by activation of the stress-related MAPKs: p38 and JNK and induction of stress-related genes; cell cycle arrest and apoptosis evident by increased percentages of cells in the sub-G1 fraction and Annexin V staining. In addition, we tested the response of patient-matched conditionally reprogrammed primary prostate normal and cancer cells. The tumor cells exhibited significantly higher sensitivity to the two most potent SL analogues with increased apoptosis confirmed by PARP1 cleavage compared to their normal counterpart cells. Thus, Strigolactone analogues are promising candidates for anticancer therapy by their ability to specifically induce cell cycle arrest, cellular stress and apoptosis in tumor cells with minimal effects on growth and survival of normal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.